Raphaël Rousseau has been appointed chief medical officer of Gritstone Oncology. Rousseau joins Emery, CA-based Gritstone from Roche subsidiary Genentech, where he most recently served as global franchise head for pediatrics in the firm’s Product Development Oncology division.
Rousseau’s hire follows Gritstone’s recent promotion of Roman Yelensky to chief technology officer. Gritstone is developing a personalized cancer vaccine treatment based on neoantigens, a type of protein found on the surface of cancer cells.
